Seer

Seer’s industry-defining nanoparticle technology is rooted in decades of advanced research and influenced by contributions from some of the top scientific minds of our time. Our foundation of groundbreaking scientific advancement is on display in Clarivate's new Highly Cited Researchers 2024 list, where our visionary Chair and CEO, Omid Farokhzad, along with esteemed Scientific Advisory Board members Robert Langer, Steven Carr, Luis Diaz, and Chris Mason are once again recognized for their significant and broad influence in their respective fields of research. Congratulations and thank you for your enduring impact on scientific innovation. Omid Farokhzad, M.D., Chair and CEO at Seer Robert Langer, Sc. D, Institute Professor at the Massachusetts Institute of Technology Steven Carr, Ph.D, Senior Director of Proteomics at Broad Institute and Harvard Luis Diaz, M.D., Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Christopher Mason Ph.D, Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine; Director of the WorldQuant Initiative for Quantitative Prediction

Seer’s industry-defining nanoparticle technology is rooted in decades of advanced research and influenced by contributions from some of the top scientific minds of our time. Our foundation of groundbreaking scientific advancement is on display in Clarivate's new Highly Cited Researchers 2024 list, where our visionary Chair and CEO, Omid Farokhzad, along with esteemed Scientific Advisory Board members Robert Langer, Steven Carr, Luis Diaz, and Chris Mason are once again recognized for their significant and broad influence in their respective fields of research. Congratulations and thank you for your enduring impact on scientific innovation. Omid Farokhzad, M.D., Chair and CEO at Seer Robert Langer, Sc. D, Institute Professor at the Massachusetts Institute of Technology Steven Carr, Ph.D, Senior Director of Proteomics at Broad Institute and Harvard Luis Diaz, M.D., Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Christopher Mason Ph.D, Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine; Director of the WorldQuant Initiative for Quantitative Prediction

Thank you to Adil Ali, MD, for speaking with Seer President and CFO David Horn to get his insights into why proteomics has become more critical than ever, some of the exciting work our customers and partners are doing, and what's ahead for Seer.   We look forward to the full Vital Signs report, produced by Onyx, which will be published in Fortune soon.

For the 2nd year in a row, Seer ranked as one of the Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast500™. We’re proud to be recognized for the continued validation of our work, providing customers and the broader scientific community with the power to enable deep proteomic insights at a scale and price point that hasn’t been possible before. 'This has been an exciting year for Seer, from the launch of our technology access center in Europe, to seeing our Proteograph platform used by astronauts on the SpaceX Inspiration4 mission, to the recent announcement of our co-marketing and sales agreement with Thermo Fisher Scientific,' said David Horn, Seer’s President and CFO. https://loom.ly/nyLMK3k #Proteomics #Collaboration #Innovation #LifeSciences #Seer #ScientificBreakthroughs #HealthTech #Fortune500 #TechGrowth #Biotech #ScientificInnovation #LifeScienceInnovation

Please join us at the Czech Annual Cancer Research Meeting. We would welcome the opportunity to explore the power of proteomics with you at our presentation session. https://loom.ly/129BXU0 Date: Tuesday, 19 Nov 2024, 15:15-15:30 CET Presented by: Maik Pruess, PhD, Senior Field Application Scientist. Session: Early Cancer Detection and Prevention Unraveling the proteome by untargeted mass spectrometry proteomics at scale VENUE: 3rd Conference of the National Institute for Cancer Research Hotel NH Collection Olomouc Congress Legionarska 21 Olomouc 779 00 Czech Republic

Seer’s collaboration with Thermo Fisher Scientific will expand the global reach of Seer's Proteograph™ Product Suite, enabling more researchers to access this technology. Seer’s workflow uncovers critical insights from the dynamic and complex proteome that other methods miss. With the Proteograph™ XT assay kit, researchers can detect rare protein variants and novel protein biomarkers in a seamless process that is accurate, precise, and reproducible across a wide variety of sample types and sizes. #Proteomics #Collaboration #Innovation #LifeSciences #ThermoFisher #Seer #ScientificBreakthroughs #HealthTech #Proteograph

Transforming Proteomics: Seer and Thermo Fisher Scientific Join Forces to Accelerate Breakthroughs in Life Sciences This strategic collaboration aims to create a seamless sample-to-data workflow, offering life science researchers unprecedented access to advanced tools for uncovering deeper insights into human biology and disease. Together, we are pushing the boundaries of what is possible in proteomics, empowering researchers to drive meaningful discoveries and innovations. “This collaboration represents a pivotal step in our mission to transform proteomics by integrating our Proteograph™ Product Suite with Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometers,” said Omid Farokhzad, CEO and Chair of Seer. “Thermo Fisher Scientific mass spectrometers set the gold standard for proteomics. By enabling Thermo Fisher Scientific customers to acquire the Proteograph™ Product Suite in conjunction with a Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer, we are expanding access to these powerful tools and setting a new standard in proteomics that has the potential to accelerate scientific discoveries and ultimately improve human health.” #Proteomics #Collaboration #Innovation #LifeSciences #ThermoFisher #Seer #ScientificBreakthroughs #HealthTech #Proteograph

We are thrilled about the groundbreaking collaboration between Seer and Thermo Fisher Scientific, which combines sensitivity, accuracy, and scalability to enable deep, unbiased proteomics. Together, we are advancing proteomic workflows to create a seamless sample-to-data experience. Read the full press release here: https://loom.ly/_8AjcaU By integrating our Proteograph™ Product Suite with Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer, we aim to deliver impactful data that drives biological insights for academic and commercial researchers alike. This partnership pushes the boundaries of what is possible in life sciences, paving the way for new discoveries and innovations. #Proteomics #Collaboration #Innovation #LifeSciences #ThermoFisher #Seer #ScientificBreakthroughs #HealthTech #Proteograph

Thank you for visiting us at #ASHG24! We would love to continue to explore how we can help you push your #genomicsresearch forward with the power of #proteomics and our #Proteograph technology. We invite you to schedule a follow-up 1:1 here: https://lnkd.in/gRAcKp_h. #proteomicsresearch #proteogenomics #proteomicstechnology #humanbiology #biologicalinsights #ProteographProductSuite

We are thrilled to announce a new co-marketing and sales agreement with Thermo Fisher Scientific to accelerate the adoption of cutting-edge proteomic technologies. This strategic collaboration will integrate Seer’s Proteograph™ Product Suite with Thermo Fisher Scientific’s industry-leading Orbitrap Astral™ mass spectrometers, providing researchers with a powerful, scalable solution for deep, unbiased proteomic analysis at scale. https://lnkd.in/gHY6TiQM #proteomics #collaboration #innovation #lifesciences #ThermoFisher #Seer #scientificbreakthroughs #healthtech #Proteograph